1. Home
  2. CLDX
  3. CLDX News

Latest Celldex Therapeutics Inc. (CLDX) News on September 15, 2025

Celldex Therapeutics (CLDX) Reports Promising Phase 2 Study Results For Barzolvolimab
CLDX

Simply Wall St.

5 days ago

Celldex Therapeutics (CLDX) Reports Promising Phase 2 Study Results For Barzolvolimab

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
CLDX

GlobeNewswire

3 months ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
CLDX

GlobeNewswire

3 months ago

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
CLDX

Zacks

3 months ago

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
CLDX

GlobeNewswire

3 months ago

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
CLDX

GlobeNewswire

3 months ago

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain
CLDX

Insider Monkey

4 months ago

Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
CLDX

Zacks

4 months ago

Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates

CLDX

Associated Press Finance

4 months ago

Celldex: Q1 Earnings Snapshot

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
CLDX

GlobeNewswire

4 months ago

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
CLDX

GlobeNewswire

4 months ago

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

CLDX

MT Newswires

5 months ago

Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
CLDX

Zacks

6 months ago

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?

CLDX

MT Newswires

6 months ago

Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target

Celldex Therapeutics to Present at Upcoming Investor Conferences
CLDX

GlobeNewswire

6 months ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
CLDX

GlobeNewswire

6 months ago

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
CLDX

GlobeNewswire

7 months ago

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Celldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line
CLDX

Simply Wall St.

7 months ago

Celldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
CLDX

Zacks

7 months ago

Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates

CLDX

Associated Press Finance

7 months ago

Celldex: Q4 Earnings Snapshot

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
CLDX

GlobeNewswire

7 months ago

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Celldex Therapeutics And 2 Other Undervalued Small Caps With Insider Action In US
CLDX

Simply Wall St.

8 months ago

Celldex Therapeutics And 2 Other Undervalued Small Caps With Insider Action In US

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans
CLDX

Simply Wall St.

8 months ago

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

January 2025's Undervalued Small Caps With Insider Action On US Markets
CLDX

Simply Wall St.

8 months ago

January 2025's Undervalued Small Caps With Insider Action On US Markets

Is There An Opportunity With Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) 26% Undervaluation?
CLDX

Simply Wall St.

8 months ago

Is There An Opportunity With Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) 26% Undervaluation?

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
CLDX

GlobeNewswire

9 months ago

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
CLDX

Zacks

9 months ago

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?

CLDX

MT Newswires

10 months ago

Celldex Therapeutics Doses First Patient in Study of Potential Inflammatory Disease Treatment

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
CLDX

GlobeNewswire

10 months ago

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Celldex Therapeutics to Present at Upcoming Investor Conferences
CLDX

GlobeNewswire

10 months ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations
CLDX

Simply Wall St.

10 months ago

Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
CLDX

Zacks

10 months ago

Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates

CLDX

Associated Press Finance

10 months ago

Celldex: Q3 Earnings Snapshot

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
CLDX

GlobeNewswire

10 months ago

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Celldex selloff creates buying opportunity, says Guggenheim
CLDX

TipRanks

a year ago

Celldex selloff creates buying opportunity, says Guggenheim

Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years
CLDX

Simply Wall St.

a year ago

Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
CLDX

GlobeNewswire

a year ago

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
CLDX

GlobeNewswire

a year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

Celldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical Results
CLDX

Insider Monkey

a year ago

Celldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical Results

Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks
CLDX

Insider Monkey

a year ago

Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks

CLDX

MT Newswires

a year ago

Citigroup Initiates Celldex Therapeutics at Buy With $70 Price Target

CLDX

MT Newswires

a year ago

Goldman Sachs Initiates Coverage on Celldex Therapeutics With Neutral Rating, $45 Price Target

CLDX

MT Newswires

a year ago

Wolfe Research Downgrades Celldex Therapeutics to Peer Perform From Outperform

CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
CLDX

Zacks

a year ago

CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study

CLDX

MT Newswires

a year ago

Wells Fargo Upgrades Celldex Therapeutics to Overweight From Equalweight After Barzolvolimab Data

CLDX

MT Newswires

a year ago

Wells Fargo Upgrades Celldex Therapeutics to Overweight From Equalweight

CLDX

MT Newswires

a year ago

Celldex Therapeutics Says New Barzolvolimab Data Show Sustained Efficacy in Urticaria

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
CLDX

GlobeNewswire

a year ago

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
CLDX

GlobeNewswire

a year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

Celldex Therapeutics, Inc. (CLDX): Short Seller Sentiment is Bearish on This Cancer Stock
CLDX

Insider Monkey

a year ago

Celldex Therapeutics, Inc. (CLDX): Short Seller Sentiment is Bearish on This Cancer Stock

Celldex Therapeutics to Present at Upcoming Investor Conferences
CLDX

GlobeNewswire

a year ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Therapeutics Second Quarter 2024 Earnings: Beats Expectations
CLDX

Simply Wall St.

a year ago

Celldex Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
CLDX

Zacks

a year ago

Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates

CLDX

Associated Press Finance

a year ago

Celldex: Q2 Earnings Snapshot

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
CLDX

GlobeNewswire

a year ago

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
CLDX

GlobeNewswire

a year ago

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Invest In Growth
CLDX

Simply Wall St.

a year ago

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Invest In Growth

Caribou lays off staff; Roche walks away from Relay
CLDX

BioPharma Dive

a year ago

Caribou lays off staff; Roche walks away from Relay

CLDX

MT Newswires

a year ago

Celldex Therapeutics Launches Phase 3 Trials for Barzolvolimab in Patients With Chronic Skin Inflammation

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
CLDX

GlobeNewswire

a year ago

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

CLDX

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 06/12/2024

Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ...
CLDX

GuruFocus.com

a year ago

Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ...

CLDX

MT Newswires

a year ago

Celldex Therapeutics Insider Sold Shares Worth $1,586,844, According to a Recent SEC Filing

CLDX

MT Newswires

a year ago

Wolfe Research Initiates Coverage on Celldex Therapeutics With Outperform Rating, $51 Price Target

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)
CLDX

GuruFocus.com

a year ago

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

Media Advisory - Prime Minister's itinerary for Saturday, June 8, 2024
CLDX

CNW Group

a year ago

Media Advisory - Prime Minister's itinerary for Saturday, June 8, 2024

CLDX

GlobeNewswire

a year ago

NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Annual Report on Form 10-Q

CORUS PROVIDES UPDATE ON PROGRAMMING AND TRADEMARK OUTPUT ARRANGEMENTS
CLDX

CNW Group

a year ago

CORUS PROVIDES UPDATE ON PROGRAMMING AND TRADEMARK OUTPUT ARRANGEMENTS

Ciscom Corp. to Hold Annual and Special Meeting of the Shareholders on August 20, 2024
CLDX

Newsfile

a year ago

Ciscom Corp. to Hold Annual and Special Meeting of the Shareholders on August 20, 2024

Camber Energy Announces Passing of Director Lawrence Fisher
CLDX

ACCESSWIRE

a year ago

Camber Energy Announces Passing of Director Lawrence Fisher

ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72
CLDX

GlobeNewswire

a year ago

ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders
CLDX

GlobeNewswire

a year ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

CLDX

MT Newswires

a year ago

Celldex Therapeutics Insider Sold Shares Worth $1,579,353, According to a Recent SEC Filing

CLDX

MT Newswires

a year ago

Celldex Therapeutics Insider Sold Shares Worth $1,964,088, According to a Recent SEC Filing

Celldex Therapeutics to Present at Jefferies Healthcare Conference
CLDX

GlobeNewswire

a year ago

Celldex Therapeutics to Present at Jefferies Healthcare Conference

CLDX

MT Newswires

a year ago

Celldex Therapeutics Insider Sold Shares Worth $1,191,775, According to a Recent SEC Filing

CLDX

MT Newswires

a year ago

Celldex Therapeutics Insider Sold Shares Worth $1,319,156, According to a Recent SEC Filing

CLDX

MT Newswires

a year ago

Celldex Therapeutics Insider Sold Shares Worth $1,298,384, According to a Recent SEC Filing

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
CLDX

GlobeNewswire

a year ago

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
CLDX

Zacks

a year ago

Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet

CLDX

MT Newswires

a year ago

Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
CLDX

GlobeNewswire

a year ago

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
CLDX

Zacks

a year ago

Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade

Celldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
CLDX

Simply Wall St.

a year ago

Celldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

CLDX

Associated Press Finance

a year ago

Celldex: Q1 Earnings Snapshot

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
CLDX

GlobeNewswire

a year ago

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
CLDX

GlobeNewswire

a year ago

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
CLDX

Zacks

a year ago

Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)

All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
CLDX

Zacks

a year ago

All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy

Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
CLDX

Zacks

a year ago

Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)

Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
CLDX

Zacks

a year ago

Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
CLDX

GlobeNewswire

2 years ago

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
CLDX

GlobeNewswire

2 years ago

Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CLDX

GlobeNewswire

2 years ago

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
CLDX

GlobeNewswire

2 years ago

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?
CLDX

Zacks

2 years ago

Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know
CLDX

Zacks

2 years ago

Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know

Celldex Therapeutics Announces Proposed Public Offering of Common Stock
CLDX

GlobeNewswire

2 years ago

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Celldex Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
CLDX

Simply Wall St.

2 years ago

Celldex Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Celldex Stock Rockets 28% On A Promising New Hives Treatment
CLDX

Investor's Business Daily

2 years ago

Celldex Stock Rockets 28% On A Promising New Hives Treatment

Share on Social Networks: